Featured posts

0 3039

There are some lawmakers out there who believe the United States will legalize marijuana all across the nation within the next five-to-10 years. The only problem with this prediction is they have been spewing the same unsubstantiated blah-blah-blahs for the past two decades.

It seems that handicapping the death of prohibition in our fair land is not exactly easy to do, especially considering that the country is still mostly governed by stiff-collar conservative forces that subscribe to the opinion that marijuana legalization will bring about the demise of civil society. What’s worse is these shrews are convinced that this supposed disembowelment of the American soul will happen one child at a time… starting with yours!

However, if Congress does no drop the propaganda-laden political shenanigans and make some effort to put this long-overdue reform on the books sometime within the next 100 years, it is conceivable that the human race will literally suffer extinction before the majority of us, including our children, ever get a chance to find out what it means to live in a world where marijuana is handled no differently than alcohol.

At least that seems to be the opinion of renowned physicist Stephen Hawking, who, in a new BBC documentary called Expedition New Earth, explains the world is doomed to its untimely death if humanity fails to colonize another planet within the next several decades.

“With climate change, overdue asteroid strikes, epidemics and population growth, our own planet is increasingly precarious,” Hawking explained.

This prediction is slightly more unnerving than Hawking’s previous theory, which suggested the human race would likely be wiped out sometime within the next 1,000 years—a timeline that did not invoke much concern among that portion of the population that still lies awake at night haunted by the mysteries that come with being born.

However, for those people living with small children, the latest hypothesis indicates that the youth of today could be part of the adult population that either has to find a way to inhabit other planetary jurisdictions or be snuffed out in a manner of which is only known by the dinosaurs. And according to science, they never made a comeback.

“Although the chance of disaster to planet Earth in a given year may be quite low, it adds up over time, and becomes a near certainty in the next 1,000 or 10,000 years,” Hawking said during a lecture last November at Oxford University.

“By that time, we should have spread out into space, and to other stars, so a disaster on Earth would not mean the end of the human race,” he added. “However, we will not establish self-sustaining colonies in space for at least the next hundred years, so we have to be very careful in this period.”

Hawking advises humans to find a way to inhabit the moon or Mars as a way to evade a total catastrophe on Earth. Fortunately, there is already a legion of scientists working to put people on Mars within the next 20 years.

“I’m excited to announce that we are working with our commercial partners to build new habitats that can sustain and transport astronauts on long-duration missions in deep space,” former President Barack Obama wrote in 2016. “These missions will teach us how humans can live far from Earth—something we’ll need for the long journey to Mars.”

But then again, living on the Red Planet would be cold, dark and depressing—sort of like living in a desert, only it never gets even close to warm and there is no weed, Taco Bell or pizza delivery within 50 miles. The second coming of humanity would undoubtedly suck far worse than even the darkest days on planet Earth.

But for the sake of future generations, let’s hope that Stephen Hawking is about as accurate with his latest doomsday prediction as federal lawmakers have been about nationwide marijuana legalization.

0 1406

Here’s some counterintuitive news for those who have been hammered all their lives with claims that cannabis causes memory loss.

A new study by scientists at the University of Bonn, written up in the journal Nature Medicine, found that aging mice treated with daily small doses of THC actually experienced a reversal of cognitive decline. That is, they started doing better on cognitive tasks, such as going through a maze.

The researchers foresee potential cannabis-based treatment to fend off dementia.

“If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care, then that is more than we could have imagined,” said study leader Andras Bilkei-Gorzo.

The bad news for stoners is that the study found that the THC applications had the reverse effect in young mice—hindering their cognitive capabilities.

But it will be interesting to see what kind of media splash this makes. So far, the study has been written up in the Guardian but has mostly been covered by niche sites like Medical XPress and Popular Science.

In February 2016, when a study from researchers at Switzerland’s University of Lausanne found a link between years of daily cannabis use and a middle-age decline in short-term memory (as measured in verbal skills), it was written up in the Washington Post. We’ll see if WaPo now covers the new findings.

And in January 2016, University College London researchers found no impact of cannabis on the IQ of young users. The IQs of young cannabis users and non-users was virtually identical. These findings were noted in Science magazine but failed to win much mainstream coverage.

Back in July 2011, Time magazine did allow a guest editorial by Maia Szalavitz on a study that followed 2,000 Australians through young adulthood, finding no difference in cognitive abilities between cannabis users and non-users.

0 683

Cannabidiol otherwise known as CBD is a compound found in marijuana. Though there are dozens of cannabinoids, which are the chemical properties found in marijuana products that create the effects linked with cannabis consumption, CBD is one of the most plentiful. It’s second only to THC.

On December 15 the DEA concluded their decision to add CBD oil to the Schedule 1 drug list, which means it must meet certain standards.

The federal government named marijuana a Schedule I drug in 1970 primarily for the psychoactive effects of THC. Prior to December, CBD remained in a regulatory gray area.

A Schedule I drug must meet three criteria to be included on the list:

1.The drug or substance has a high potential for abuse.
2.The drug or substance has no currently accepted medical use in the United States.
3.There is a lack of accepted safety standards for use of the drug or other substance under medical supervision.

The CBD classification was made despite recent investigative studies that has preliminarily shown CBD to have anti-inflammatory, analgesic as well as anti-anxiety properties without the psychoactive effects of THC.

Most of the investigative research is still in its beginning stages and opponents of the reclassification complain that CBD fails to meet the Schedule I criteria based on the initial discoveries.

Although CBD is a cannabis component, the CBD-specific industry is a little different from the larger cannabis industry.

“We do have THC-CBD products, but in the recreational industry we are not allowed to sell anything that doesn’t also have THC in it,” said Amanda Woods, Compliance Officer and Marketing Manager for Choice Organics. “So, a lot of the CBD products free-floating throughout the market were derived from hemp, which does not have the same regulations that cannabis does.”

Hemp is most commonly defined as a legal cannabis product derived from the plant’s stem. Hemp has been used for many different purposes from rope to textile fibers to nutritional supplements to medicinal oils. To be defined as hemp, the product must contain very little THC — less than one percent. For comparison, THC levels in medical cannabis are anywhere between five and 20 percent.

Hemp that contains minimal THC can still contain high amounts of other cannabinoids, like CBD. In Colorado and nationwide, you can walk into a gas station—not even a licensed dispensary— and find CBD products made from hemp. However, these products come from unregulated sources and may pose a public safety hazard.

“[Before December], CBD-only products derived from hemp could be distributed nationwide. You could send CBD in the mail and you could order it on Amazon,” Woods said.

Without the THC, hemp products avoided the strict regulations legal cannabis advocates have fought for.

“On one hand, the [rescheduling] is a step in the right direction in that it forces regulation of this gray market. Like cannabis, it will be up to the State to decide to regulate hemp like cannabis if there is to be an intra-state market. Regulation is good for everyone,” Woods said. “But it is also unfortunate because it was made into a Schedule I drug which only reinforces the federal prohibition on cannabis products… So, there was no real change for the cannabis industry in Colorado, but it has a major impact on the hemp industry.”

Marijuana Stocks

It’s a Done Deal! Just as we had suspected, Vinergy Resources (VNNYF) today announced the signing of a definitive agreement to acquire 100% of MJ Biopharma, a cannabis technology company. We have been speculating for over a week that the halt of trading on the Canadian exchange for symbol VIN.CN was to allow for this completed acquisition, and we were right. The stock has gained as much as 36% since we re-initiated coverage on VNNYF last week in anticipation of this deal closing. But now the real fun begins…

This is a major milestone for VNNYF and its shareholders that gives a true fundamental boost to the company. The investment community has been waiting for closure on this item for some time now dating back months ago when the company first mentioned its plans for the acquisition. Back then Vinergy’s stock skyrocketed on the possibility of the deal closing but soon pulled back as investors perhaps grew tired of waiting for a definitive deal, or maybe they doubted the whole deal altogether.

Well, now today’s news from VNNYF of a signed definitive agreement will put all that uncertainty and impatience to rest while sparking a new level of interest and excitement.

Incentivized Compensation Plan

Perhaps the most exciting piece of this acquisition is the means in which Vinergy is acquiring MJ Biopharma. 4.25M shares of common stock priced at $0.20CAD are to be issued upfront, 2/3 of which will be held in escrow. But MJ Biopharma management and shareholders have the opportunity to earn an additional 5M shares is they bring each of their 4 product segments to commercialization. This is a genius move by VNNYF management that could drastically increase shareholder value down the road.

What is VNNYF Acquiring?

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems;


MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.


The Big Picture is Starting to Come Together

The company said their novel approach for its breath strip technology may become the basis for new products where water or saliva is the catalyst to activate the carrier for delivery and absorption of CBD into the body. Management believes this breakthrough could form the basis of a new technology and has the potential to create an entirely new product category. The technology is called BURST, named for the speed at which it enhances the body’s absorption of various ingredients.

And let’s not forget that VNNYF signed a binding letter of intent to acquire 65% of Biolennia Laboratories. Biolennia Labs is a specialty development laboratory with expertise in microbiology and chemistry. The lab operates out of a secure facility in Toronto alongside Micrylium, which manufactures products registered under license from several agencies. It currently provides testing, R&D, and quality control for Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrylium.

Vinergy also reported the development of a disruptive solvent-based extraction system. The project is already underway and the company will be providing updates and more information soon. Positive results from this project could be another strong catalyst for VNNYF. And with the acquisition of MJ Biopharma finally completed, all the pieces appear to be falling perfectly into place.

What was once speculation and hype that ignited nearly a 200% move in Vinergy’s stock months ago when this acquisition was just a “possibility” has just officially become reality. The structure of this deal and the current market conditions could present great opportunity for VNNYF shareholders. So far we have seen VNNYF gain as much as 36% since we re-initiated coverage on the company but with this acquisition finally in the books, this could be just the beginning.

Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2137
cannabis biotech

VANCOUVER, BRITISH COLUMBIA–(MarijuanaStocks.com – May 9, 2017) – Vinergy Resources Ltd. (“Vinergy” or the “Company”) (CSE:VIN)(VNNYF) is pleased to announce that it has signed a definitive agreement (the “Agreement“) with 1099955 B.C. LTD. dba MJ BioPharma (“MJ BioPharma“) whereby Vinergy will purchase 100% of MJ BioPharma, a cannabis technology company. Pursuant to the terms of the Agreement, the Company will acquire all of the issued and outstanding securities of MJ BioPharma (the “Transaction“).

About MJ BioPharma

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems.

MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.

Definitive Agreement

Pursuant to the terms of the Agreement, the Company will, upon closing of the Transaction, issue to MJ BioPharma shareholders an aggregate of 9,750,000 common shares in the capital of the Company (the “Payment Shares”) at a deemed price of CDN$0.20 per Payment Share. The Payment Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”). A finder’s fee of 400,000 common shares in the capital of the Company, subject to CSE approval, will be payable on this Transaction.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

0 502

Germany started 2017 with a surprise…when the largest country in the European Union legalized medical cannabis for people suffering from debilitating illnesses.

Although Germany began to permit patient access to medical cannabis in 2005, domestic production does not currently exist. Until state-supervised cannabis plantations are set up, the country will continue to rely solely on imported products.

Under the new law, people suffering from serious illnesses such as multiple sclerosis, chronic pain, or a lack of appetite and nausea could access medical cannabis.

Insurance to Cover Cost for German Patients

Germany’s bill will make cannabis available through health insurance plans, which should result in a significantly higher patient adoption rate.

Health Minister Hermann Groehe said to Reuters, “Those who are severely ill need to get the best possible treatment and that includes health insurance funds paying for cannabis as a medicine for those who are chronically ill if they can’t be effectively treated any other way.”

Could Have 1 Million Patients Instantly

Germany is a massive opportunity. With over 82 million inhabitants the country is twice the size of California and reports have shown that 23.1% of the adult population has consumed cannabis.

When you do the math, that comes out to almost 19 million people, which creates a massive market could easily be five times larger than Canada’s medical cannabis market.

Authored By: Michael Berger

0 1656

Although the United States legal cannabis train has already left the station, President Donald Trump’s first 100 days have raised some concerns.

The best way to describe his first 100 days is something like a rocket fueled roller coaster and we want to highlight the top 5 developments that have transpired thus far.

• West Virginia became the 29th state to legalize medical cannabis after Governor Jim Justice signed legislation to create a legal program in the state. The program will allow patients suffering with terminal illnesses or any of 14 specified conditions access to cannabis.
• Jeff Sessions has been shut down once again as the budget bill that passed to prevent a government shutdown contained a provision known as the Rohrabacher-Farr amendment, which has United States cannabis business owners breathing a sigh of relief. The provision will make sure that no portion of Department of Justice’s budget will be allowed to be used to attempt to fight state laws allowing for the use of medical marijuana.
• After Colorado Governor John Hickenlooper met with Attorney General Jeff Sessions he does not expect there to be a federal crackdown on legal cannabis. Governor Hickenlooper said Sessions called the Obama administration’s guidance on marijuana not too far from good policy.
• Department of Homeland Security Secretary John Kelly called marijuana a potentially dangerous gateway drug that frequently leads to the use of harder drugs the day after he said that cannabis is not a factor in the United States’ current fight against narcotics.
• In February, White House Press Secretary Sean Spicer attempted to link cannabis use to the opioid addiction crisis plaguing the United States. He said the President understands the value of medical cannabis for those in need, but recreational cannabis is an issue for the Department of Justice to provide further clarification.

Authored By: Michael Berger

0 1004

The medical cannabis market in Canada continues to grab headlines after the country announced plans to legalize recreational cannabis on a national level before July 1, 2018.

This opportunity has created ample opportunities for everyone. From funds to companies, the Canadian legal cannabis market continues to report significant developments.

In April, Horizons ETFs Management launched the first medical cannabis focused exchange traded fund (ETF) called the Horizons Medical Marijuana Life Sciences ETF. The fund trades under the symbol HMMJ on the Toronto Stock Exchange. Although the fund has generated incredible interest, it has not lived up to expectations so far and HMMJ is down 4.1% since it started trading

Passively Managed ETF Doesn’t Work for Cannabis Stocks

Although the Medical Marijuana Life Sciences ETF is designed to be a liquid and investable index of publicly listed companies focused on the cannabis industry, it is not designed to handle volatile periods like the one we have experienced over the last month.

HMMJ is an index (or passively managed) ETF, designed to provide exposure to a basket of North American publicly traded companies with significant business activities in the cannabis industry.

For this reason, we think the ETF may have launched at the complete wrong time. HMMJ started trading right before legislation was tabled by the Canadian federal government. The Canadian cannabis market rallied into this event, but has since pulled back and is look for a bottom.

Don’t End Up in a Liquidity Trap

When it comes to Canadian medical cannabis producers, we are very focused on the recent decrease in trading volume. Across the board (from Aurora to Canopy, from Aphria to Emblem), trading volume has decreased significantly and this is one of the most important metrics to follow.

Trading volume has an immediate impact on a stock’s spread (difference between the buy and sell price) and we continue to closely monitor how this trend continues. If this weak volume trend continues, we expect to see HMMJ trade lower and continue to prefer investing in individual companies at this time.

0 1499

In a data-driven business environment, everyone is waiting on the most up to date statistical reports to show what direction consumers are spending their money. As a relatively new industry, the legalized marijuana sector still is working on how to best assist consumers and discern trends to sort out the hype from the reality. That’s created a whole new side business in marijuana: data analytics.

A company that has stepped to the forefront in this area is New Frontier Data. The company has partnered with Baker Technologies, which provides customer relationship management and marketing automation platforms to cannabis businesses, for access to an immense database of legal marijuana transactions.

In April, based on this data, the company released its annual “The Cannabis Industry Report: 2017 Legal Marijuana Outlook.” They uncovered some interesting trends.

Medical marijuana dominates the market. Recreational marijuana is otherwise known as the adult-use marijuana which has been the center of much of the recent media attention, partially because of its reflection of the wholesale change in how millions of Americans view marijuana. Voter have now made recreational marijuana legal in eight states: Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon, and Washington, as well as the District of Columbia.

However, the report found that consumers of medical marijuana — legal in more than half the states — buy much more frequently and spend more than recreational users. The report included the following findings:

In 2016, recreational users shopped for cannabis, on average, every 14 days and spent $49 per transaction. That same year, medical marijuana users shopped every 10 days and spent $136 per transaction. In 2017, medical marijuana sales are expected to total $5.3 billion, with a projection to reach $13.2 billion annually by 2025.
In 2017, recreational marijuana sales are expected to reach $2.6 billion, with a projection to reach $10.9 billion by 2025. The numbers provide needed insight for entrepreneurs looking to enter the retail cannabis business, New Frontier Data CEO Giadha Aguirre De Carcer said in a news release.

“Given the size of the market, knowing who your customers are, how and when they shop, and what they buy are fundamental building blocks of developing any effective retail strategy,” he said.

0 3694

Attorney General Jeff Sessions is certainly riled up to challenge state marijuana laws. Sadly for him, Congress just extinguished his chances.

The recent 1,665-page spending bill has a requirement that restricts the Department of Justice from using any of its finances to hinder state laws linked to medical marijuana. The department cannot “prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana,” Section 537 of the bill reads.

The $1.1 trillion spending bill—the Consolidated Appropriations Act, H.R. 244 (PDF)—passed the Senate back on May 4, with a 79-to-18 vote. The White House has indicated that Trump will sign it, which will keep the government operating until September.

The section that ties the hands of the Department of Justice on medical marijuana enforcement isn’t anything new. It has been around since back in 2015. But it received little fanfare amid the Obama era, which took a mild position on enforcing federal marijuana laws in states that have some form of legalized marijuana program.

All that changed when Jeff Sessions obtained control of the Department of Justice. Sessions has frequently stated he is against marijuana legalization and indicated that he would abandon Obama’s lax enforcement position.

For example, back in an April 2016 Congressional Hearing, Sessions announced that “good people don’t smoke marijuana.” When Sessions was asked about enforcement this February at a press conference, he said:

“I am definitely not a fan of expanded use of marijuana. But states, they can pass the laws they choose. I would just say, it does remain a violation of federal law to distribute marijuana throughout any place in the United States, whether a state legalizes it or not.”

With Section 537, Sessions can still make an effort to fight the recreational use of marijuana in the eight states that have passed such laws. However, without funding, Sessions’ has little ability to fight the medical marijuana laws in 29 states and the District of Columbia.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements